Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Pfizer
M.D. Anderson Cancer Center
Erasca, Inc.
Jonsson Comprehensive Cancer Center
Pfizer
Actym Therapeutics, Inc.
Ikena Oncology
Eli Lilly and Company
Columbia University
Thomas Jefferson University
Theratechnologies
Sotio Biotech Inc.
ABM Therapeutics Corporation
National Cancer Institute (NCI)
MacroGenics
Fore Biotherapeutics
Celgene
Celgene
University of Chicago
Calando Pharmaceuticals
Rutgers, The State University of New Jersey